Clinical trials: COVID-19, SARS-CoV-2
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Covid 19
GlowTest COVID-19 Antigen Home Test Kit QRI Use Study
The objective of the study is to determine the usability of the GlowTest COVID-19 Antigen Home Test in a simulated home use environment.
- Trial name
- NCT05140005
- Testing
- GlowTest COVID-19 Antigen Home Test
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Arion Bio
Influenza, Human, COVID-19
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season.
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B
- Trial name
- WAVE (NCT06207929)
- Where
- United States
- Volunteers
- 18,157 people, healthy volunteers welcome
- Sponsor
- Evidation Health
COVID-19
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups.
- Trial name
- NCT05373472
- Testing
- COVID-19 mRNA vaccine
- Where
- 3 sites in China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065879
- Testing
- COVAX
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Sepsis, COVID-19
SQuISH-COVID: A Pilot Study
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious…
- Trial name
- NCT04372472
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cytovale, Inc.
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-VA (NCT05663957)
- Testing
- Evusheld
- Where
- United States
- Volunteers
- 5,814 people
- Sponsor
- AstraZeneca
Severe Acute Respiratory Syndrome Coronavirus 2
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
- Trial name
- COVID-19 (NCT04522986)
- Testing
- Mesenchymal stem cell
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Coronavirus Infection, COVID-19
Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
A randomized, double-blind, placebo-controlled, adaptive, seamless phase I / II clinical study of the safety and immunogenicity of a recombinant viral vector AAV5-RBD-S vaccine for the prevention of coronavirus infection…
- Trial name
- COVER (NCT05037188)
- Testing
- Low dose BCD-250 injection, High dose BCD-250 injection, Low dose or high dose BCD-250 injection
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biocad
COVID19
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Trial name
- NCT05175690
- Testing
- Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
Efficacy of Adaptogens in Patients With Long COVID-19
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible…
- Trial name
- NCT04795557
- Testing
- ADAPT-232 oral solution
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- Swedish Herbal Institute AB
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.